$69.37
1.9%
Price vs. AI Score (Last 150 days)
Data gathered: November 29
Data gathered: November 29
Data Bits
| Data Bits | Value / Change | Benchmark |
|---|---|---|
| Job Posts | 2 0% |
|
| Sentiment | 85 -12.4% |
|
| Webpage traffic | 79,000 21.3% |
|
| Employee Rating | 60 0% |
|
| Google Adspend | $ N/A | N/A |
| Google Trends | 26 188.9% |
|
| Linkedin Employees | 494 N/A |
|
| Patents | 189 0.5% |
|
| 4chan Mentions | 0% |
|
| Stocktwits Mentions | 54 3.8% |
|
| Stocktwits Subscribers | 35,863 0% |
|
| Twitter Followers | 20,735 0% |
|
| Instagram Followers | N/A | N/A |
| News Mentions | 3 0% |
|
| Reddit Mentions | 1 0% |
|
| Business outlook | 43 0% |
|
In the news
 |
CRISPR Gene Editing: Intellia Vs. Crispr TherapeuticsNovember 28 - SeekingAlpha |
Notice of Special Interest (NOSI): Development and Application of Novel Chemical Approaches to Discover Therapeutic Targets for Substance Use DisordersNovember 28 - National Institutes of Health |
|
 |
Pro Research: Wall Street deep dive on Vertex Pharmaceuticals growth avenuesNovember 27 - Investing.com |
 |
Rethinking cancer? Study reveals mutant protein’s role in tumor growthNovember 27 - New Atlas |
3 Top-Rated Biotech Stocks That Analysts Are Loving NowNovember 27 - InvestorPlace |
|
 |
Crispr Therapeutics: The Party Is Over (Rating Downgrade)November 27 - SeekingAlpha |
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
| Price | $69.37 |
| Target Price | Sign up |
| Market Cap | $5.64B |
| Dividend Yield | 0 |
| Industry | Biotechnology |
Similar companies
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
|---|---|---|---|---|---|
| Q3 '23 | 0 | 18M | -18M | -112M | -132M |
| Q2 '23 | 70M | 19M | 51M | -78M | -90M |
| Q1 '23 | 100M | 22M | 78M | -53M | -64M |
| Q4 '22 | 6,000 | 21M | -21M | -111M | -132M |
| Q3 '22 | 94,000 | 27M | -27M | -175M | -177M |
Insider Transactions
| Kulkarni Samarth filed to sell 387,377 shares at $66.8. June 1 '23 |
| Kulkarni Samarth filed to sell 387,377 shares at $51.5. April 27 '23 |
| Kulkarni Samarth filed to sell 387,377 shares at $44.8. March 31 '23 |
| Kulkarni Samarth filed to sell 375,988 shares at $49.2. March 1 '23 |
| Kulkarni Samarth filed to sell 369,111 shares at $51.5. January 31 '23 |
Read more about Crispr Therapeutics and their earnings, price prediction, job posts, sentiment, webpage traffic, employee rating, google adspend, google trends, linkedin employees, patents, 4chan mentions, stocktwits mentions, stocktwits subscribers, twitter followers, instagram followers, news mentions, reddit mentions, business outlook.